Effect of enoxaparin on subacute in-stent thrombosis after stenting in patients with symptomatic middle cerebral artery stenosis / 国际脑血管病杂志

ABSTRACT

Objective:To investigate whether the use of enoxaparin after stenting in patients with symptomatic middle cerebral artery stenosis can reduce the risk of subacute in-stent thrombosis (IST).Methods:Patients with symptomatic middle cerebral artery stenosis underwent stenting in the Department of Neurology, Drum Tower Clinical Medical School, Nanjing University of Chinese Medicine from January 2020 to December 2022 were retrospectively included. The patients were divided into an enoxaparin group and a control group based on whether to use enoxaparin after surgery. The demographic and baseline data and the incidence of perioperative complications were compared between the two groups. Multivariate logistic analysis was used to determine the independent influencing factors of postoperative subacute IST.Results:A total of 86 patients were enrolled, including 61 males (70.93%), and aged 58.03±10.14 years old. Forty-eight patients (55.81%) were treated with enoxaparin. The incidence of subacute IST in the enoxaparin group was significantly lower than that in the control group (2.08% vs. 13.16%; χ2=4.008, P=0.045), and there was no statistically significant difference in the incidence of symptomatic intracranial hemorrhage compared to the control group (2.08% vs. 2.63%; χ2=0.028, P=0.867). Multivariate logistic regression analysis showed that the use of enoxaparin after stenting was an independent protective factor of subacute IST (odds ratio 0.042, 95% confidence interval 0.005-0.901; P=0.042). Conclusion:The use of enoxaparin after stenting in patients with symptomatic middle cerebral artery stenosis can reduce the incidence of subacute IST without increasing the incidence of symptomatic intracranial hemorrhage.